// App-Quantinova.ai

5074 : Re-treatment with radium-223: An international, prospective, open-label study in patients with castration-resistant prostate cancer and bone metastases.

Researchers

Presenter

  • A. Oliver Sartor

Principal Investigators

  • Daniel Heinrich

  • Neil Mariados

  • Maria Jose Mendez-Vidal

  • Daniel Keizman

  • Camilla Thellenberg-Karlsson

  • Avivit Peer

  • Giuseppe Procopio

  • Stephen Jay Frank

  • Kalevi Pulkkanen

  • Eli Rosenbaum

  • Stefano Severi

  • Jose Manuel Trigo Perez

  • Paul Schwarzenberger

  • Rui Li

  • Luke T. Nordquist

Medical Centers

  • Tulane Cancer Center, New Orleans, LA

  • Akershus University Hospital, Lorenskog, Norway

  • Associated Medical Professionals of NY, PLLC, Syracuse, NY

  • Hospital Universitario Reina Sofia, Cordoba, Spain

  • Meir Medical Center, Kfar-Saba, Israel

  • Cancercentrum Norrlands Universitetssjukhus, Umea, Sweden

  • Rambam Medical Center, Haifa, Israel

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • Hadassah-Hebrew-University-Medical-Cente, Jerusalem, Israel

  • Kuopio University Hospital, Kuopio, Finland

  • Rabin Medical Center, Davidoff Center, Petah Tikva, Israel

  • Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

  • IBIMA-Hospital Regional Universitario y Virgen de la Victoria, Malaga, Spain

  • Pharmaceuticals Division of Bayer, Whippany, NJ

  • GU Research Network, LLC, Omaha, NE

Locations

  • Finland

  • Norway

  • Italy

  • Spain

  • United States

  • Israel

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

  • Bone metastases

  • Prostate cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Enzalutamide

  • CB-7598

  • Radium-223 Dichloride

Outcome

  • N/A

Study Design

  • Open Label

  • Multinational

  • Prospective

Phase

  • NA

Study Id's

  • NCT01934790

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved